JanOne Inc. Quarterly report pursuant to Section 13 or 15(d)

Intangible Assets

3 Months Ended

Mar. 30, 2024

Note 7: Intangible Assets

Intangible assets as of March 30, 2024 and December 30, 2023 consist of the following (in $000’s):


	March 30, 2024		December 30, 2023
Soin intangibles *	$	19,293	$	19,293
Patents and domains	4		4
Intangible assets	19,297		19,297
Less accumulated amortization	(2,090)		(1,451)
Total intangible assets	$	17,207	$	17,846

*The Soin intangibles acquired by the Company consist of the following:

1.Two pending patents and one approved patent related to the methods of using low-dose Naltrexone to treat chronic pain;

2.Final formula for Naltrexone; and

3.Orphan drug designation as approved by the FDA.

Intangible amortization expense was $639,000 and $363,000 for the 13 weeks ended March 30, 2024 and April 1, 2023, respectively.